Exposure-response analyses of liraglutide 3.0 mg for weight management
-
J. P. Wilding; R. V. Overgaard; L. V. Jacobsen; C. B. Jensen; C. W. le Roux
Exposure-response analyses of liraglutide 3.0 mg for weight management Diabetes Obes Metab
Publication Category: Weight Loss/Management
Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis
-
P. M. Ryan; S. Seltzer; N. E. Hayward; D. A. Rodriguez; R. T. Sless; C. P. Hawkes
Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis J Pediatr
Routine clinical use of liraglutide 3 mg for the treatment of obesity: Outcomes in non-surgical and bariatric surgery patients
-
M. Suliman; A. Buckley; A. Al Tikriti; T. Tan; C. W. le Roux; N. Lessan; M. Barakat
Routine clinical use of liraglutide 3 mg for the treatment of obesity: Outcomes in non-surgical and bariatric surgery patients Diabetes Obes Metab
Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial
-
J. S. Tronieri; T. A. Wadden; O. A. Walsh; R. I. Berkowitz; N. Alamuddin; K. Gruber; S. Leonard; A. M. Chao
Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial Metabolism
Prescribing for weight loss in primary care: evidence from a population based study
-
L. Patterson; C. Patterson; F. Kee; C. Hughes; M. Donnelly; D. O'Reilly
Prescribing for weight loss in primary care: evidence from a population based study J Epidemiol Community Health
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
-
X. Pi-Sunyer; A. Astrup; K. Fujioka; F. Greenway; A. Halpern; M. Krempf; D. C. Lau; C. W. le Roux; R. Violante Ortiz; C. B. Jensen; J. P. Wilding
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management N Engl J Med
Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial
- D. Papamargaritis; W. Al-Najim; J. Lim; J. Crane; M. Lean; C. le Roux; B. McGowan; D. O'Shea; D. Webb; J. Wilding; M. J. Davies Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial BMJ Open
Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial
- R. J. McCrimmon; A. M. Catarig; J. P. Frias; N. L. Lausvig; C. W. le Roux; D. Thielke; I. Lingvay Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial Diabetologia
The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme
-
C. Le Roux; D. C. W. Lau; K. Fujioka; I. D. Caterson; A. P. Cancino; C. B. Jensen; M. E. J. Lean
The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme Diabetologia